dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
Published 4 years ago • 247 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
1:49
dr. mcgregor on new combinations with immunotherapy in rcc
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:35
checkmate-9er shows efficacy of nivolumab/cabozantinib combo in rcc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:06
dr. toni choueiri on nivolumab and cabozantinib becoming first-line therapies in rcc
-
5:58
checkmate 9er update confirms benefits of nivolumab–cabozantinib in rcc | cristina suárez
-
6:37
cabozantinib in combination with nivolumab demonstrated continued survival and hrqol in arcc pat...
-
0:55
dr. apolo on the combination of cabozantinib plus nivolumab in urothelial carcinoma
-
1:23
checkmate 9er: nivolumab with cabozantinib in renal cell carcinoma
-
4:01
nivolumab–cabozantinib boosts advanced rcc outcomes | andrea apolo
-
1:56
checkmate 9er: arcc patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
-
2:05
esmo 2020 highlights on nivolumab cabozantinib as 1st line therapy for arcc: the checkmate 9er study
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
1:46
dr. meric-bernstam on cb-839 plus cabozantinib in rcc